First Patients Recruited and Enrolled in Cellceuti

First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin

Elsevier Business Intelligence  Reports Cellceutix “ Developing A Still-Secret Prodrug For Psoriasis” and a “Heralded Cancer Candidate”

BEVERLY, MA – October 29, 2012-- Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that the first patients have been recruited and enrolled for the clinical trials of Kevetrin™, the Company’s novel cancer drug in development.  The clinical trials are being conducted on patients with advanced solid tumors at Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.

Based on dialogue with the clinical sites, the Company anticipates updating shareholders next week that dosing of the first patient has been administered.

“We are extremely pleased to hear that the first patients will begin therapy with Kevetrin™ in a matter of days,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.  “Not only is this is a substantial milestone for Cellceutix and its shareholders, but we feel it is important to the field of oncology.  As a novel compound that directly impacts p53, the “Guardian Angel of the Human Genome,” we look forward to a steady patient enrollment and future outcomes that potentially could change the landscape of cancer therapeutics.

Elsevier Business Intelligence

Cellceutix announced that Elsevier Business Intelligence has released a profile article on the Company for its latest edition of its publication “Start Up: Emerging Medical Ventures.”

Elsevier, a division of Reed Elsevier Group PLC, is the world’s leading provider of science and health information, serving more than 30 million scientists, students and health and information professionals worldwide.

In the article, Elsevier’s Deborah Erickson discusses the uniqueness of the Company’s Prurisol™ as a new therapeutic candidate for psoriasis, and the clinical trials at Dana-Farber Cancer Center and Beth Israel Deaconess on Kevetrin™ as a novel, p53-activating anti-cancer drug.  Regularly referencing Cellceutix as “anything but a normal start-up,” the write-up provides a succinct overview of the Company, its “all-star” advisory staff and offers insight into Kevetrin and Prurisol.

Shareholders and interested parties are encouraged to view the article at: http://cellceutix.com/category/in-the-news/

“We are very pleased to have been approached by Elsevier.  They have a tremendous global outreach and the additional exposure is positive for our company,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix.  “I found it particularly interesting how attracted they were to Prurisol and the incredible potential that they see for the drug.  Because of the p53 connection and strong possibilities for Kevetrin™, many people overlook how impactful and valuable Prurisol can be as well.”